INmune Bio Inc is a clinical stage biotechnology pharmaceutical company focused on developing and commercializing its product candidates to treat diseases where inflammation and immunology cause a dysfunctional immune system contributing to disease. The company's pipeline products include INKmune, XPro1595, and others. It has three product platforms; The CORDStrom product platform, The DN-TNF product platform, and The Natural Killer Cell Priming Platform.
Last trade$0.9843
Day change+$0.0379 (+4.00%)
Day range$0.922 – $1.04
Volume510,803
Market cap$29M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$29.41M
Price / earnings
—
Price / book
1.63×
Price / sales
—
EV / sales
—
EV / EBITDA
-0.75×
Profitability
Earnings per share
-$0.55
Return on assets
-78.82%
Return on equity
-93.8%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0×
Current ratio
6.41×
Quick ratio
6.41×
Cash ratio
5.6×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$13.49M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for INMB, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$0
$0
$0
$0
$0
$0
$50K
$0
Cost of revenue
$0
$0
$0
$0
$0
$0
$0
$0
Gross profit
$0
$0
$0
$0
$0
$0
$50K
$0
Selling, general and administrative
$1.85M
$2.28M
$2.17M
$3.15M
$2.55M
$2.25M
$2.32M
$2.11M
Research and development
$3.16M
-$803K
$3.64M
$2.33M
$4.89M
$5.8M
$7.64M
$7.35M
Total operating expenses
$5.01M
$1.48M
$5.81M
$5.47M
$7.43M
$24.57M
$9.96M
$9.47M
Operating income
-$5.01M
-$1.48M
-$5.81M
-$5.47M
-$7.43M
-$24.57M
-$9.91M
-$9.47M
Interest expense
$0
$0
$0
$0
$0
$0
$0
$0
Income before taxes
-$5.01M
-$1.27M
-$5.41M
-$5.26M
-$7.43M
-$24.46M
-$9.74M
-$9.22M
Income taxes
$0
$0
$0
$0
$0
$0
$0
$0
Net income
-$5.01M
-$1.27M
-$5.41M
-$5.26M
-$7.43M
-$24.46M
-$9.74M
-$9.22M
Net income attributable to common shareholders
-$5.01M
-$1.27M
-$5.41M
-$5.26M
-$7.43M
-$24.46M
-$9.74M
-$9.22M
EBITDA
-$4.94M
-$1.41M
-$5.76M
-$5.42M
-$7.41M
-$8.06M
-$9.91M
-$9.47M
Basic earnings per share
-$0.17
-$0.05
-$0.20
-$0.20
-$0.24
-$1.05
-$0.43
-$0.41
Diluted earnings per share
-$0.17
-$0.05
-$0.20
-$0.20
-$0.24
-$1.05
-$0.43
-$0.41
Recent news
Company coverage with links to the original publishers.
Quantum Computing Inc. (QUBT) reported Q3 2026 revenues of $9.5M, exceeding expectations, driven by acquisitions of photonics businesses. The company is prioritizing commercialization and manufacturing expansion, with a $39.1M contract backlog and plans for $70-80M in FAB 2 investment. However, profitability remains challenged with a 4.5% gross margin, and the company carries a Zacks Rank #4 (Sell) rating.
Over 200 companies are advancing more than 240 pipeline Alzheimer's disease therapies across various clinical development stages. The market is being driven by an aging population, rising disease prevalence, and the emergence of disease-modifying therapies that enable earlier intervention and biomarker-guided care. Two therapies have recently received FDA approval: KISUNLA (donanemab) from Eli Lilly and LEQEMBI (lecanemab-irmb) from Eisai/Biogen, both targeting amyloid plaques to slow disease progression.
INmune Bio announced statistically significant results from its Phase 2 MINDFuL trial of XPro1595 in early Alzheimer's disease patients. The drug showed a significant treatment effect on white matter myelin (p=0.0028) in the full study population (n=200) and strengthened further in inflammation-enriched patients (p=0.0098). The company has secured FDA Fast Track designation and End-of-Phase 2 alignment for an integrated Phase 2b/3 registrational program.
INmune Bio Inc. (NASDAQ: INMB) announced that Phase 2 MINDFuL trial results for XPro™ (XPro1595, pegipanermin) in mild Alzheimer's disease with inflammation have been published in NPJ Dementia. In a pre-specified enriched subgroup (n=100) with amyloid-beta positivity and inflammation biomarkers, XPro™ showed directionally consistent benefits across cognitive, functional, behavioral, and biomarker endpoints over 24 weeks with no serious adverse events. The company received FDA Fast Track designation for the program.
INmune Bio announced that the FDA has granted Fast Track designation to XPro (pegipanermin), a first-in-class selective soluble TNF inhibitor, for treating early Alzheimer's disease including mild cognitive impairment and mild dementia. The designation facilitates expedited development and review, recognizing the urgent need for treatments addressing neuroinflammation in Alzheimer's. The company plans to execute a Phase 2b/3 precision-medicine registrational program targeting patients with biomarkers of inflammation.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.